Amounts other than Medicare schedule fees (for example out-of-pocket costs, price ranges and worked examples) are indicative and vary by provider and circumstances. Confirm current figures with the provider or the official source.
Part of the GP Vaccine Hub — all immunisation tools & NIP updates.
👩⚕️ Clinical reference for health professionals. This page summarises published clinical guidance and is not medical advice. Patients and members of the public: please don’t use this to make decisions about your own care — talk to your GP, pharmacist or travel clinic.
⚠️ Tier 2 — use clinical judgement. Qdenga is a new, non-NIP vaccine in Australia and ATAGI advice may be updated as more data become available. Always verify at the ATAGI statement before clinical decisions. Page last reviewed 27 October 2026.
ATAGI recommended / can-consider groups, dosing, storage and reconstitution, contraindications, co-administration, billing and AIR recording.
🇦🇺 AUATAGI / TGASep 2026
📋 Sources — reviewed 27 October 2026:
1. ATAGI — Statement on the clinical use of the dengue vaccine (Qdenga) for Australians, Version 1, 24 September 2026. health.gov.au ↗ 2. TGA — AusPAR decision summary, Qdenga. tga.gov.au ↗ 3. TGA — Qdenga Product Information (AusPAR, approved June 2026). tga.gov.au ↗ 4. Dept of Health and Aged Care — Mandatory reporting changes to the Australian Immunisation Register (AIR), 1 March 2025. health.gov.au ↗ 5. RACGP newsGP — Dengue vaccine available in Australia, 5 October 2026. racgp.org.au ↗ Editorial independence: This page was written and fact-checked independently by AskMyGP from the ATAGI statement and TGA Product Information. No pharmaceutical company has had editorial input into, reviewed, or approved this content. See our Editorial Independence & Funding policy.
Schedule: two doses, 0.5 mL each, at 0 and 3 months (minimum 12 weeks). No booster currently recommended — insufficient evidence (ATAGI).
Route: subcutaneous injection, preferably in the upper arm over the deltoid. Must not be given intravascularly, intradermally or intramuscularly (TGA PI).
Storage (before use): refrigerate at 2–8°C in original packaging. Do not freeze.
Reconstitution: use only the solvent supplied (0.22% sodium chloride solution). Withdraw the full solvent volume, inject toward the side of the vial while slowly depressing the plunger, then gently swirl — do not shake (foaming can occur). Solution should clear in 30–60 seconds; discard if particulates or discolouration are present.
After reconstitution: administer immediately. If not possible, use within 2 hours and do not return to the fridge.
Observation: 15-minute post-injection observation is advised, as for any injectable vaccine — ATAGI notes a reported anaphylaxis rate with Qdenga higher than typically seen with vaccination in general.
Contraindicated: immunocompromise (including starting immunosuppressive treatment within 4 weeks), symptomatic HIV infection, pregnancy, breastfeeding, and anaphylaxis to a previous Qdenga dose or any excipient (TGA PI lists pregnancy and breastfeeding as contraindications; ATAGI phrases pregnancy as “not recommended,” with individual risk–benefit consideration only if travel to a dengue area is unavoidable).
Precaution: postpone vaccination during an acute severe febrile illness (TGA PI).
Recent dengue infection: ATAGI suggests considering deferring Qdenga for about 6 months after a confirmed or likely episode, reflecting short-lived cross-protection against all serotypes after natural infection.
No routine pre-vaccination serology: ATAGI does not recommend testing for past dengue before vaccination, partly due to flavivirus antibody cross-reactivity. Base prior-dengue status on a lab-confirmed episode or clinical assessment of a compatible illness history.
Vaccine-associated enhanced disease (VAED): unlike the earlier Dengvaxia (no longer available in Australia), Qdenga has not been linked to VAED in the millions of doses given globally (ATAGI).
✓Same-day with non-live vaccines (e.g. hepatitis A)
✓Same-day with other live injected vaccines (e.g. Japanese encephalitis, MMR, yellow fever)
✓Same-day with oral live vaccines (e.g. cholera, typhoid)
⚠If not given same-day as another live injected vaccine, leave at least 4 weeks between them
⚠Use separate injection sites when multiple vaccines are given at the same visit; giving several at once may slightly increase mild–moderate side effects
🛫 Pre-travel planning & one-dose fallback
Book early: the 12-week minimum interval between doses means a patient needs to start at least 3 months before departure to complete the course pre-travel. Stock and lead times for ordering from Takeda vary by practice — order ahead of a known travel date.
If only one dose fits before travel: ATAGI still recommends giving dose 1 — trial data showed ~82% efficacy against confirmed dengue in the 3 months after a single dose, with sustained protection over 12 months in outbreak-setting studies. Document a plan for dose 2, either on return or with a provider at the destination.
Bite avoidance is not replaced by vaccination — continue to advise standard mosquito-avoidance measures regardless of vaccination status.
💳 Billing, funding & AIR recording
Not NIP-funded. Qdenga is supplied on private prescription only. There is no specific MBS immunisation-administration item for it — bill the consultation as a standard attendance item (e.g. Level A/B) reflecting the time and complexity of the visit, and charge the vaccine cost separately as a private fee. Practices set their own vaccine and administration pricing.
AIR recording: mandatory AIR reporting currently covers NIP vaccines, COVID-19, influenza and Japanese encephalitis vaccines — Qdenga is not on that mandatory list as of the March 2025 reporting changes. Recording it on the AIR anyway is good practice: it gives the patient a verifiable record for future providers or a destination clinic giving dose 2.
Indicative patient cost: roughly $165–185 per dose (AskMyGP estimate, not a published price) — about $330–370 for the full two-dose course, plus any consultation fee. See the patient guide for the cost caveat to share with patients.
📱 Sharing with patients
Use the Share using QR code bar above to show the patient-facing guide on-screen or send the link directly. It includes a dose-timing planner (dose 2 earliest date, from the dose 1 date) and a situation-based FAQ.